Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedGuide-Only REMS Will Be The Exception, Not The Norm, As FDA Relaxes Policy

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA’s proposed new benchmark for incorporating a Medication Guide in a Risk Evaluation and Mitigation Strategy would reduce the regulatory burden on sponsors whose products do not warrant restricted distribution measures.
Advertisement

Related Content

Unintended Consequences Of REMS Weighed On Entyvio Review Team
Human Genome Sciences Dodges Mortality Boxed Warning, REMS For Benlysta
Human Genome Sciences Dodges Mortality Boxed Warning, REMS For Benlysta
PhRMA Wants MedGuides Developed The Pre-FDAAA Way, Not Through REMS
"MedGuides" Required Only In Classes Where Patient Info Already Requested

Topics

Advertisement
UsernamePublicRestriction

Register

PS004696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel